MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
44.74
-0.28 (-0.62%)
At close: Jul 19, 2024, 4:00 PM
44.77
+0.03 (0.07%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
MLTX Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for MLTX stock have an average target of 76.33, with a low estimate of 59 and a high estimate of 104. The average target predicts an increase of 70.61% from the current stock price of 44.74.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for MLTX stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +123.51% | Jul 1, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $104 | Buy | Initiates | $104 | +132.45% | Jun 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +123.51% | Jun 11, 2024 |
| Needham | Needham | Strong Buy Reiterates $66 | Strong Buy | Reiterates | $66 | +47.52% | Jun 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $100 | Strong Buy | Reiterates | $100 | +123.51% | May 17, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.28
from -0.73
EPS Next Year
-2.00
from -1.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | 277.2M | 1.0B |
| Avg | n/a | n/a | n/a | 136.1M | 585.1M |
| Low | n/a | n/a | n/a | 53.4M | 239.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 659.7% |
| Avg | - | - | - | - | 329.9% |
| Low | - | - | - | - | 75.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.86 | -1.17 | -2.05 | -0.20 | 2.33 |
| Avg | -1.28 | -2.00 | -2.88 | -2.10 | 0.89 |
| Low | -1.78 | -2.74 | -3.76 | -3.03 | -1.57 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.